Could a menopause drug combo cut breast cancer risk?

NCT ID NCT04821141

Ongoing Prevention Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a daily pill combining bazedoxifene and conjugated estrogens can reduce breast cancer risk in 120 women aged 45-64 who have menopausal hot flashes and are at increased risk for breast cancer. Participants take the drug for 6 months or join a waitlist. Researchers measure changes in breast density and cell growth markers to see if risk may be lowered.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bazedoxifene plus conjugated estrogens (BZA+CE)
What this could lead to: If successful, this could point toward a hormone-based option to lower breast cancer risk in women with menopausal symptoms.
What could go wrong: This is a small, early-phase trial testing only biomarker changes, not actual cancer reduction. Results may not lead to a proven prevention method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Hot Flashes Risk Reduction Behavior breast cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER RISK REDUCTION

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Northwestern Medical Center

Chicago, Illinois, 60601, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University of California San Francisco

San Francisco, California, 94115, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.